Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 154 No. 9 (2024)

Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies

DOI
https://doi.org/10.57187/s.3559
Cite this as:
Swiss Med Wkly. 2024;154:3559
Published
09.09.2024

Summary

Immunoglobulins for intravenous use (IVIgs) and subcutaneous use (SCIgs) can prevent recurrent and severe infections in patients with secondary antibody deficiencies that are frequently linked to haematological/oncological malignancies as well as other clinical conditions and their respective treatments. Even so, as IVIgs and SCIgs are costly and their supply is limited, their clinical use must be optimised. The aim of this position paper is to provide structured practical guidance on the optimal use of IVIgs and SCIgs in secondary antibody deficiencies, particularly in haematological and oncological practice.

The authors agree that the occurrence of severe infections is a prerequisite for the use of IVIgs. Serum IgG levels in general as well as IgG subclass levels can be additional indicators of whether a patient could benefit from IVIgs. Responsiveness to vaccines can help to identify immunodeficiency. Patients with chronic lymphocytic leukaemia or multiple myeloma who are receiving respective treatment, especially B-cell depletion therapy, but also some patients with autoimmune diseases are prone to antibody deficiencies and need IVIgs. For the optimal use of IVIgs and to maximise their potential benefit, the indication must be individually assessed for each patient. As a primary treatment goal, the authors define a sufficient prophylaxis of severe infections, which can be supported by normalising IgG levels. If the initiated treatment is insufficient or linked to intolerable adverse reactions, switching the product within the class of IVIgs or changing to a different batch of the same product can be considered. Pausing treatment can also be considered if there are no infections, which happens more frequently in summer, but treatment needs to be resumed once infections return.

These structured recommendations for IVIg treatment in patients with secondary antibody deficiency may provide guidance for clinical practice and therefore help to allocate IVIgs to those who will benefit the most, without overusing valuable resources.

References

  1. Na IK, Hensel M, Maschmeyer G, Scheibenbogen C, Wehr C. Daniel Wolff KW. Onkopedia Leitlinie: Immundefekte sekundär. 2019. Available from: https://www.onkopedia.com/de/onkopedia/guidelines/immundefekte-sekundaer/@@guideline/html/index.html
  2. Sánchez-Ramón S, Bermúdez A, González-Granado LI, Rodríguez-Gallego C, Sastre A, Soler-Palacín P; ID-Signal Onco-Haematology Group. Primary and secondary immunodeficiency diseases in oncohaematology: warning signs, diagnosis, and management. Front Immunol. 2019 Mar;10(MAR):586. doi: https://doi.org/10.3389/fimmu.2019.00586 DOI: https://doi.org/10.3389/fimmu.2019.00586
  3. Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: Causes, diagnosis, and management. Front Immunol. 2019 Feb;10:33. doi: https://doi.org/10.3389/fimmu.2019.00033 DOI: https://doi.org/10.3389/fimmu.2019.00033
  4. Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014 Dec;5(DEC):626. DOI: https://doi.org/10.3389/fimmu.2014.00626
  5. Vivarelli E, Matucci A, Bormioli S, Parronchi P, Liotta F, Cosmi L, et al. Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2-year real-life experience. Clin Exp Immunol. 2021 Sep;205(3):346–53. doi: https://doi.org/10.1111/cei.13629 DOI: https://doi.org/10.1111/cei.13629
  6. Gale RP, Chapel HM, Bunch C, Rai KR, Foon K, Courter SG, et al.; Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988 Oct;319(14):902–7. doi: https://doi.org/10.1056/NEJM198810063191403 DOI: https://doi.org/10.1056/NEJM198810063191403
  7. Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023 Nov;4(6):440–51. doi: https://doi.org/10.1158/2643-3230.BCD-23-0049 DOI: https://doi.org/10.1158/2643-3230.BCD-23-0049
  8. Novaretti MC, Dinardo CL. Immunoglobulin: production, mechanisms of action and formulations. Rev Bras Hematol Hemoter. 2011;33(5):377–82. doi: https://doi.org/10.5581/1516-8484.20110102 DOI: https://doi.org/10.5581/1516-8484.20110102
  9. European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). IVIg) Eur Med Agency Comm Med Prod Hum Use (CHMP). 2018 Jun;44(June 2018). Available from: http://www.ema.europa.eu/htms/human/qrd/docs/convention.pdf
  10. Bundesamt fuer Gesundheit (BAG). Specialty list, state August 2020. 2020 Aug. Available from: www.spezialitätenliste.ch
  11. Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al.; TEAMM Trial Management Group and Trial Investigators. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1760–72. doi: https://doi.org/10.1016/S1470-2045(19)30506-6 DOI: https://doi.org/10.1016/S1470-2045(19)30506-6
  12. Jolles S, Michallet M, Agostini C, Albert MH, Edgar D, Ria R, et al. Treating secondary antibody deficiency in patients with haematological malignancy: european expert consensus. Eur J Haematol. 2021 Apr;106(4):439–49. doi: https://doi.org/10.1111/ejh.13580 DOI: https://doi.org/10.1111/ejh.13580
  13. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 Dec;25(12):2305–21. doi: https://doi.org/10.1016/j.bbmt.2019.08.015 DOI: https://doi.org/10.1016/j.bbmt.2019.08.015
  14. Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol. 2010 Mar;159(3):344–50. doi: https://doi.org/10.1111/j.1365-2249.2009.04062.x DOI: https://doi.org/10.1111/j.1365-2249.2009.04062.x
  15. Leitao Filho FS, Ra SW, Mattman A, Schellenberg RS, Criner GJ, Woodruff PG, et al.; Canadian Respiratory Research Network (CRRN). Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respir Res. 2018 Feb;19(1):30. doi: https://doi.org/10.1186/s12931-018-0733-z DOI: https://doi.org/10.1186/s12931-018-0733-z
  16. Umetsu DT, Ambrosino DM, Quinti I, Siber GR, Geha RS. Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency. N Engl J Med. 1985 Nov;313(20):1247–51. doi: https://doi.org/10.1056/NEJM198511143132002 DOI: https://doi.org/10.1056/NEJM198511143132002
  17. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009 May;50(5):764–72. doi: https://doi.org/10.1080/10428190902856824 DOI: https://doi.org/10.1080/10428190902856824
  18. Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, et al. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: long-term data of the SIGNS study. Eur J Haematol. 2017 Aug;99(2):169–77. doi: https://doi.org/10.1111/ejh.12900 DOI: https://doi.org/10.1111/ejh.12900
  19. Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Jan;32(1):23–33. doi: https://doi.org/10.1016/j.annonc.2020.09.019 DOI: https://doi.org/10.1016/j.annonc.2020.09.019
  20. Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb;9(2):e143–61. doi: https://doi.org/10.1016/S2352-3026(21)00283-0 DOI: https://doi.org/10.1016/S2352-3026(21)00283-0
  21. Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, et al. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Clin Infect Dis. 2018 Aug;67(5):687–92. doi: https://doi.org/10.1093/cid/ciy175 DOI: https://doi.org/10.1093/cid/ciy175
  22. Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: A systematic review and meta-analysis. Am J Hematol. 2018 Mar;93(3):339–47. doi: https://doi.org/10.1002/ajh.24976 DOI: https://doi.org/10.1002/ajh.24976
  23. Serra Font S, López-Granados L, Sisinni L, Serna Berna JV, Martínez Martínez L, Fernández de Gamarra-Martínez E, et al. Chronic hypogammaglobulinemia after allogeneic stem cell transplantation and their treatment with subcutaneous immunoglobulin in pediatric patients. An Pediatr (Engl Ed). 2022 Aug;97(2):103–11. doi: https://doi.org/10.1016/j.anpede.2021.08.010 DOI: https://doi.org/10.1016/j.anpede.2021.08.010
  24. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006 Apr;6(4):592–9. doi: https://doi.org/10.1016/j.intimp.2005.11.003 DOI: https://doi.org/10.1016/j.intimp.2005.11.003
  25. Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs. 2005;28(6):366–74. doi: https://doi.org/10.1097/00129804-200511000-00003 DOI: https://doi.org/10.1097/00129804-200511000-00003
  26. Cuesta H, El Menyawi I, Hubsch A, Hoefferer L, Mielke O, Gabriel S, et al. Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations. Transfusion. 2022 Sep;62(9):1894–907. doi: https://doi.org/10.1111/trf.17028 DOI: https://doi.org/10.1111/trf.17028
  27. Nolan BE, Wang Y, Pary PP, Luban NL, Wong EC, Ronis T. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease. Transfusion. 2018 Nov;58(11):2564–71. doi: https://doi.org/10.1111/trf.14879 DOI: https://doi.org/10.1111/trf.14879
  28. Quinti I, Pulvirenti F, Milito C, Granata G, Giovannetti G, La Marra F, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion. 2015 May;55(5):1067–74. doi: https://doi.org/10.1111/trf.12939 DOI: https://doi.org/10.1111/trf.12939
  29. Pendergrast J, Armali C, Callum J, Cserti-Gazdewich C, Jiwajee A, Lieberman L, et al.; QUEST Research Program. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis. Transfusion. 2021 Apr;61(4):1053–63. doi: https://doi.org/10.1111/trf.16232 DOI: https://doi.org/10.1111/trf.16232
  30. Bellac CL, Hottiger T, Jutzi MP, Bögli-Stuber K, Sänger M, Hanschmann KM, et al. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. Transfusion. 2015 Jul;55(S2 Suppl 2):S13–22. doi: https://doi.org/10.1111/trf.13113 DOI: https://doi.org/10.1111/trf.13113
  31. Wallenhorst C, Patel A, Shebl A, Hubsch A, Simon TL, Martinez C. Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study. Transfusion. 2020 Jul;60(7):1381–90. doi: https://doi.org/10.1111/trf.15859 DOI: https://doi.org/10.1111/trf.15859
  32. Product information. Cuvitru®. 2021 Jun.
  33. Product information. Hizentra®. 2022 Oct.
  34. Product information. Cutaquiq®. 2022 Mar.
  35. Product information. Hyqvia®. 2018 Dec.
  36. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):106–11. doi: https://doi.org/10.1016/j.clml.2012.11.011 DOI: https://doi.org/10.1016/j.clml.2012.11.011
  37. Sim BZ, Longhitano A, Er J, Harrison SJ, Slavin MA, Teh BW. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 2023 Mar;13(1):34. doi: https://doi.org/10.1038/s41408-023-00808-8 DOI: https://doi.org/10.1038/s41408-023-00808-8
  38. Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, et al. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. Oncologist. 2020 Feb;25(2):e321–7. doi: https://doi.org/10.1634/theoncologist.2019-0233 DOI: https://doi.org/10.1634/theoncologist.2019-0233
  39. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al.; ZUMA-7 Investigators; Kite Members. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul;389(2):148–57. doi: https://doi.org/10.1056/NEJMoa2301665 DOI: https://doi.org/10.1056/NEJMoa2301665
  40. https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/empfehlungen-risikogruppen-risikosituationen/empfehlungen-onkologie.pdf.download.pdf/BU_20_22_Impfempfehlung_Onkologie_DE.pdf

Most read articles by the same author(s)

1 2 > >>